【杨森生物是哪个国家的品牌？】

英文翻译：Wuhan YANGSEN Biotechnology Co., Ltd. is an enterprise engaged in R & D and agency of medical devices, established in April 2009, located in Wuhan National biological industry base, Hubei Province. Enterprises always adhere to the principle of independent innovation, and their structure and scale have been rapidly developed and expanded. The company has registered capital of RMB 500000 in 2009, and now has registered assets of RMB 7792200; it has 1000m2gmp certified production plant and 200m2 office building; at present, it has 3 invention patents and 1 utility model, 3 invention patents and 1 PCT patent have been accepted, and the company has set up 3 functional departments, including R & D department, management department and sales department; it has more than 30 employees, including Bo Bo Scholars with master's degree or above account for 83% of the total number, reflecting the independent R & D characteristics of the enterprise. The three-layer bionic small caliber artificial blood vessel project developed by Janssen company is an artificial blood vessel with reference to the structure of human own small artery. Compared with the artificial blood vessel made of pure fiber material (polyester fabric or silk) or a kind of polymer material (ePTFE), this project creatively designs a composite artificial blood vessel with three-layer structure, which is closer to the structure and function of human blood vessel. The vascular prosthesis not only simulates the three-layer anatomical structure of human arterioles (the vascular intima composed of monolayer epithelial cells, the middle layer composed of elastic smooth muscle fibers and the outer layer composed of connective tissue), but also simulates the function of each layer structure. The inner layer uses polyurethane combined with insoluble silk powder to simulate the endothelium and a small amount of connective tissue, and the middle layer uses spinning The tubular elastic fabric is made of the fabric material to simulate the elastic smooth muscle fiber layer in human blood vessels, and the outer layer is polyurethane and insoluble silk fibroin powder to simulate the connective tissue; at the same time, the gradient porous is realized from the inside to the outside along the thickness direction to simulate the microporous structure of the blood vessel wall. Core invention patent: a fabric reinforced composite artificial blood vessel, patent No.: 200610166568. The project has completed the production license certification of the project in 2014. At the end of 2014, the samples will be submitted to a third-party organization for formal review. It is expected that the third-party testing will be completed in 2015 and submitted to the State Food and Drug Administration for clinical application. The clinical trials of the project will be completed in 2016-2018. In the middle of 2018, the project's registration approval will be obtained and listed in China. During this period, strive to complete the CE certification of EU and pass the fda510k certificate at the same time, so as to open the international market of products. The company's artificial blood vessel project has been patented. At present, the artificial blood vessel has made a major breakthrough in animal experiments and is in the production stage, which will be more in line with human physiological structure. Once the product is successfully listed, it will promote the development of national industry in this field, and also has important economic and social value for the development of biomedical materials in China.

本文链接： https://www.waitui.com/brand/6bfa48b93.html 联系电话：02781888884